Trends Mergers & Acquisitions has been involved in over 200 reverse merger transactions, providing M & A services, along with capital raising capabilities to companies in the United States and internationally. With direct links to Europe, Asia, and North and South America Trends serves as a vehicle to access capital markets around the globe.
Microlin Bio (MICB) is an emerging therapeutics company focusing on microRNA and its role in oncology. MicroRNAs are recently discovered naturally-occurring RNA molecules (composed of 19 to 25 nucleotides) that do not encode proteins but instead regulate gene expression and various biological pathways. The improper balance of microRNAs is believed to be linked to many diseases, including cancer.
Ember Therapeutics (EMBT) is a biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 (BMP-7) and related family of BMPs, mutants, variants, novel formulations, and delivery technologies to develop regenerative medicines for disease modification of osteoarthritis, reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases such as chronic kidney disease and Alport Syndrome.